Abstract
Atypical antipsychotic-induced hyperprolactinemia can cause important clinical symptoms, particularly in young women and also in men, such as impotence, loss of libido, gynecomastia, anovulation and galactorrhea.
Methods: Observational over one-year follow-up of six patients (four women and two men, mean age of 31.1 years, range 26-37), treated with different atypical antipsychotics in an outpatient psychiatric device, who had clinical complications associated to high prolactin serum levels. All of them were treated with standard doses of cabergoline.
Results: Most patients experienced significant clinical improvement after treatment with standard doses of cabergoline (mean dosage 1.08 mg/week), maintained for a mean of 18 month. Normal prolactin levels were achieved after the first months of treatment with cabergoline. No side effects or worsening of psychotic or behavioral symptoms were observed.
Conclusions: Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients.
Keywords: Atypical antipsychotics, cabergoline, dopamine, hyperprolactinaemia, hypothalamus, pituitary gland, prolactin, schizophrenia.
Current Drug Safety
Title:Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Volume: 7 Issue: 2
Author(s): Ramon Coronas, Jesus Cobo, Olga Gimenez-Palop, Emilio Ortega and Manel Marquez
Affiliation:
Keywords: Atypical antipsychotics, cabergoline, dopamine, hyperprolactinaemia, hypothalamus, pituitary gland, prolactin, schizophrenia.
Abstract: Atypical antipsychotic-induced hyperprolactinemia can cause important clinical symptoms, particularly in young women and also in men, such as impotence, loss of libido, gynecomastia, anovulation and galactorrhea.
Methods: Observational over one-year follow-up of six patients (four women and two men, mean age of 31.1 years, range 26-37), treated with different atypical antipsychotics in an outpatient psychiatric device, who had clinical complications associated to high prolactin serum levels. All of them were treated with standard doses of cabergoline.
Results: Most patients experienced significant clinical improvement after treatment with standard doses of cabergoline (mean dosage 1.08 mg/week), maintained for a mean of 18 month. Normal prolactin levels were achieved after the first months of treatment with cabergoline. No side effects or worsening of psychotic or behavioral symptoms were observed.
Conclusions: Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients.
Export Options
About this article
Cite this article as:
Coronas Ramon, Cobo Jesus, Gimenez-Palop Olga, Ortega Emilio and Marquez Manel, Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics, Current Drug Safety 2012; 7 (2) . https://dx.doi.org/10.2174/157488612802715753
DOI https://dx.doi.org/10.2174/157488612802715753 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design The Role of Matrix Metalloproteinase Inhibitors in Ischemia-Reperfusion Injury in the Liver
Current Pharmaceutical Design Bivalent Ligands as Specific Pharmacological Tools for G Protein-Coupled Receptor Dimers
Current Drug Discovery Technologies Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials
CNS & Neurological Disorders - Drug Targets Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design Cardiotoxicity of 5-Fluorouracil
Cardiovascular & Hematological Agents in Medicinal Chemistry 1-Deoxynojirimycin and its Derivatives: A Mini Review of the Literature
Current Medicinal Chemistry Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Impact of Red Wine Consumption on Cardiovascular Health
Current Medicinal Chemistry Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic Targeting
Current Molecular Pharmacology Understanding Stem Cell-Mediated Brain Repair Through Neuroimaging
Current Stem Cell Research & Therapy Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Stem Cells and Nanoparticles in Therapy
Nanoscience & Nanotechnology-Asia